Tag Archives: Oxford Expression Technologies

Technology

Oxford Expression Technologies Launch Streamlined Transfection Technology

Leave a comment

Oxford Expression Technologies (OET), the award-winning specialist provider of baculovirus-based protein expression solutions, launches flashFECTIN™, a transfection reagent optimized for insect cell lines.

Oxford, UK, May 14, 2013 – Oxford Expression Technologies (OET), the award-winning specialist provider of baculovirus-based protein expression solutions, launches flashFECTIN™, a transfection reagent optimized for insect cell lines. Used in conjunction with the world renowned flashBAC™ system, the new reagent represents significant improvements with respect to ease of use, speed and affordability.

Co-transfections can be troublesome and time consuming, flashFECTIN™ has been specifically designed to address these issues, the co-transfection protocol has been highly streamlined to allow the fastest flashBAC™ reaction times to date whilst still maintaining the high efficiencies expected from the flashBAC™ system. The new transfection reagent is a non-lipid based formulation that is non-toxic to cells and is specifically optimized for insect cell lines Sf9, Sf21 and Tni.

Passing comment, James Bernard, Commercial Director at Oxford Expression Technologies said, “We are pleased to announce the launch of flashFECTIN™, our new transfection reagent to further improve the flashBAC™ system” he continued, “we are delighted that our customers can now benefit from a more affordable system with a faster and simplified protocol that still produces the same high transformation efficiencies.”

Oxford Expression Technologies invites anyone with an interest in baculovirus protein expression to visit their website – http://oetltd.com/

Oxford Expression Technologies is a biotechnology company specializing in the use of baculovirus vectors, a eukaryotic expression system that can express a large variety of recombinant proteins. Oxford Expression Technologies provides recombinant protein expression products, services and consultancy to many global pharmaceutical companies. The Company’s proprietary flashBAC technology enables large amounts of a given protein to be produced in culture. Its internationally renowned expertise and products enable proteins to be produced faster, more easily and cost-effectively using automated and high-throughput methods compared with other baculovirus expression systems. This contributes to the development of new drugs and research targeted towards understanding how proteins work in health and disease.

The company was founded in 2007 as a result of collaboration between Oxford Brookes University and the Natural Environment Research Council to provide researchers with custom proteins for research purposes.

For Further information or an illustrative image:
Media contact – Mathew Taylor, Director, Algorythm Solutions Ltd, mobile: +44 (0)773 403 2112, email: mtaylor@algorythmsolutions.com, website: www.algorythmsolutions.com

Contact:
Mathew Taylor
Director
Algorythm Solutions Ltd
10 Torkington St
Stamford, Lincolnshire PE9 2UY
+44 (0)773 403 2112
mtaylor@algorythmsolutions.com

Homepage

Technology

Oxford Expression Technologies Launch Revolutionary Cloning Vectors

Leave a comment

Oxford Expression Technologies (OET), the award-winning specialist provider of baculovirus-based protein expression solutions, launches a new range of pOET Ligation Independent Cloning (LIC) vectors.

Oxford, UK, July 24, 2012 – Oxford Expression Technologies (OET), the award-winning specialist provider of baculovirus-based protein expression solutions, launches a new range of pOET Ligation Independent Cloning (LIC) vectors. The new LIC vectors facilitate faster and simpler gene transfer into their world renowned flashBAC system for baculovirus protein expression. They are an evolution of the easy to use and highly reliable pOET transfer vectors and provide a host of new advantages over conventional cloning methods.

As the name suggests, ligation independent cloning removes the need to undertake the ligation step in the cloning procedure, this is typically the most troublesome part of any cloning experiment so these new LIC vectors represent obvious benefits to scientists who utilize protein expression techniques.

Passing comment, Richard Broadhead, Sales and Marketing Manager at Oxford Expression Technologies said, “We are pleased to announce the launch of the new pOET ligation independent cloning vectors, they remove a problematic part of the cloning procedure and we are very pleased that we can pass these benefits on to our customers” he continued, “As well as being faster and easier, our latest innovation also allows laboratories to standardize their protocols because there is no need to take into account the length of the insert sequence to be cloned, another benefit conventional cloning methods cannot offer.”

Oxford Expression Technologies invites anyone with an interest in baculovirus protein expression to visit their website – http://oetltd.com/

Oxford Expression Technologies is a biotechnology company specializing in the use of baculovirus vectors, a eukaryotic expression system that can express a large variety of recombinant proteins. Oxford Expression Technologies provides recombinant protein expression products, services and consultancy to many global pharmaceutical companies. The Company’s proprietary flashBAC technology enables large amounts of a given protein to be produced in culture. Its internationally renowned expertise and products enable proteins to be produced faster, more easily and cost-effectively using automated and high-throughput methods compared with other baculovirus expression systems. This contributes to the development of new drugs and research targeted towards understanding how proteins work in health and disease.
The company was founded in 2007 as a result of collaboration between Oxford Brookes University and the Natural Environment Research Council to provide researchers with custom proteins for research purposes.

For Further information or an illustrative image: Media contact – Mathew Taylor, Director, Algorythm Solutions Ltd, mobile: +44 (0)773 403 2112, email: mtaylor@algorythmsolutions.com, website: www.algorythmsolutions.com

Contact:
Mathew Taylor
Director
Algorythm Solutions Ltd
10 Torkington St
Stamford, Lincolnshire PE9 2UY
+44 (0)773 403 2112
mtaylor@algorythmsolutions.com

Homepage

Technology

Oxford Expression Technologies Ltd (OET) and Trenzyme GmbH announce Bacmam Collaboration

Leave a comment

Oxford Expression Technologies Ltd (OET) and Trenzyme GmbH, both experts in the field of recombinant protein expression have agreed to collaborate so that the full potential of their complementary technologies can be realized.

Oxford, United Kingdom /Konstanz, Germany, February 27, 2012 – Oxford Expression Technologies Ltd (OET) and Trenzyme GmbH, both experts in the field of recombinant protein expression have agreed to collaborate so that the full potential of their complementary technologies can be realized. Under terms of the collaboration, both companies will be able to offer a full range of recombinant protein expression services across a variety of platforms including baculovirus, yeast, bacterial and mammalian systems.

The collaboration offers exciting possibilities in the field of the rapidly developing BacMam system, in which baculoviruses are used for protein production in mammalian cell lines. The BacMam system increases the options available to improve both the yield and quality of recombinant proteins. It also has applications in therapeutic fields including the production of recombinant vaccines and gene delivery into human cells.

Furthermore, the BacMam system fits perfectly to the Cross Organism Expression platform of Trenzyme allowing the fast and reliable screening of the best expression host for a given target protein in respect of timelines, yield and quality.

Under the terms of the collaboration, customers of both companies will be able to access the complementary technologies.

Dr Richard Broadhead, Sales and Marketing Manager at OET commented, “At OET we always aim to maximize the potential of our flashBAC baculovirus expression system. The collaboration with Trenzyme will allow us to combine our patented technology with Trenzyme’s expression platform to expand the capabilities and applications of both. Working with Trenzyme will allow us to offer our customers additional options by working with a partner who is expert in other platforms for recombinant protein expression.”

Dr Reinhold Horlacher, managing director of Trenzyme commented, “We use our Cross Organism Expression platform to streamline expression projects with high demands on timeline, yield and protein quality – the simultaneous screening in up to four expression hosts using dozens of ready-to-use expression vectors will be significantly upvalued by embedding the BacMam system. We are happy to combine the innovative power of OET and Trenzyme to offer clients of both companies tailored solutions for recombinant protein expression”

OET is a biotechnology company specializing in recombinant protein expression and a recognised centre of excellence for baculovirus expression. Based in Oxford, UK, OET provides protein expression products, services and consultancy to the biotechnology and pharma community worldwide.

OET developed the patented, industry leading flashBAC® baculovirus expression system, and has expertise in applying the system to novel related fields such as virus like particle (VLP) production. OET has an active R&D programme to deliver further enhancements and capabilities to its expanding base of clients and partners.

Trenzyme is an ISO 9001 certified service provider offering customer specific solutions in the areas of molecular biology / bio-chemistry / generation of cell lines.

Trenzyme’s international clientele consists predominantly of pharmaceutical and biotech companies, for whom customized services have been provided successfully for more than 11 years.

Classical projects range from DNA cloning / gene synthesis by means of expression in different systems (E.coli, yeast, insect cells, mammal cells) to protein purification as well as development of stable mammalian cell lines.

Trenzyme is exclusively financed by private means and is constantly expanding its clientele. Over the last couple of years the company has experienced solid revenue growth.

Further Information is available at www.trenzyme.com

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact:
Mathew Taylor
Director
Algorythm Solutions Ltd
10 Torkington St
Stamford, Lincolnshire PE9 2UY
+44 (0)773 403 2112
mtaylor@algorythmsolutions.com

Homepage